🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against superbug strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating worldwide, with data suggesting more than 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Receive Approval

One new antibiotic, alternatively called a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in the same week. This drug, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

According to findings detailed in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The trial involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have expressed positive views. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the illness for individuals and to prevent the spread of untreatable gonorrhoea globally.